scispace - formally typeset
Search or ask a question
Institution

Central Drug Research Institute

FacilityLucknow, Uttar Pradesh, India
About: Central Drug Research Institute is a facility organization based out in Lucknow, Uttar Pradesh, India. It is known for research contribution in the topics: Leishmania donovani & Brugia malayi. The organization has 4357 authors who have published 7257 publications receiving 143871 citations. The organization is also known as: Central Drug Research Institute, Lucknow & CDRI.


Papers
More filters
Journal ArticleDOI
TL;DR: An efficient natural product inspired diversity oriented syn thesis of tetrahydroquinoline analogues has been developed using the natural carbohydrate derived solid acid catalyst via multicomponent aza-Diels-Alder reaction of imine with dienophile in acetonitrile in a diastereoselective manner.
Abstract: An efficient natural product inspired diversity oriented syn thesis of tetrahydroquinoline analogues has been developed using the natural carbohydrate derived solid acid catalyst via multicomponent aza-Diels−Alder reaction of imine (generated in situ from aromatic amine and aldehyde) with dienophile in acetonitrile in a diastereoselective manner. The use of water as solvent reverses the diastereoselectivity toward the cis isomer. Interestingly, tricyclic pyrano/furano benzopyran with cis diastereoselectivity is obtained when salicylaldehyde is used as an alternative of aromatic aldehyde under the same condition. These synthesized quinolines and benzopyrans analogues have been evaluated for their Antitubercular activity against M. tuberculosis H37Ra, and M. tuberculosis H37Rv, and some of the analogues shows better activity profile than their natural product analogues. The protocol is not only mild, efficient, ecofriendly, but also involves reusable and biodegradable catalyst and provides route for both th...

98 citations

Journal ArticleDOI
TL;DR: This review includes an updated summary (2011 – 2014) of PTP1B inhibitors that have been published in patent applications, with an emphasis on their chemical structure, mode of action and therapeutic outcomes.
Abstract: Introduction: Protein tyrosine phosphatase 1B (PTP1B) plays an important role in the negative regulation of insulin signal transduction pathway and has emerged as novel therapeutic strategy for the treatment of type 2 diabetes. PTP1B inhibitors enhance the sensibility of insulin receptor (IR) and have favorable curing effect for insulin resistance-related diseases. A large number of PTP1B inhibitors, either synthetic or isolated as bioactive agents from natural products, have developed and investigated for their ability to stimulate insulin signaling.Areas covered: This review includes an updated summary (2011 – 2014) of PTP1B inhibitors that have been published in patent applications, with an emphasis on their chemical structure, mode of action and therapeutic outcomes. The usefulness of PTP1B inhibitors as pharmaceutical agents for the treatment of type 2 diabetes is also discussed.Expert opinion: PTP1B inhibitors show beneficial effects to enhance sensibility of IR by restricting the activity of enzyme...

98 citations

Journal ArticleDOI
TL;DR: It could be concluded that TPGS based nanoparticulate application is an advanced approach to improve therapeutic efficacy of chemotherapeutic agents by better internalization and sustained retention of the NPs.

97 citations

Journal ArticleDOI
TL;DR: The WS extract significantly suppressed lipopolysaccharide (LPS) induced production of proinflammatory cytokines TNF‐α, IL‐1β and IL‐12p40 in normal individuals and RA patients, but had no effect on IL‐6 production at the protein and transcript level.
Abstract: Withania somnifera (WS) is an important herb with known antiinflammatory activity. Its molecular mechanism of action has not been investigated. The effect of a WS crude ethanol extract was studied on peripheral blood mononuclear cells of normal individuals and rheumatoid arthritis (RA) patients and synovial fluid mononuclear cells of RA patients in vitro. The WS extract significantly suppressed lipopolysaccharide (LPS) induced production of proinflammatory cytokines TNF-alpha, IL-1beta and IL-12p40 in normal individuals and RA patients, but had no effect on IL-6 production at the protein and transcript level. WS also suppressed LPS activated nitric oxide production in the mouse macrophage cell line, RAW 264.7. The extract inhibited nuclear translocation of the transcription factors NF-kappaB and AP-1 and phosphorylation of IkappaBalpha in normal and RA patients' mononuclear cells. HPLC analysis of the crude extract showed the presence of withaferin A and pure withaferin A also inhibited NF-kappaB translocation. The study demonstrated that the WS crude ethanol extract suppressed the production of proinflammatory molecules in vitro. This activity is partly through the inhibition of transcription factors NF-kappaB and AP-1 by the constituent withanolide. The role of additional constituents needs to be studied. Studies on the mechanism of action of the extract may yield potentially useful compounds for the treatment of inflammatory diseases.

97 citations

Journal ArticleDOI
TL;DR: Age, focal weakness, cranial nerve palsy and hydrocephalus were found to be contributing to the three month outcome of TBM patients as assessed by the Barthel index.

97 citations


Authors

Showing all 4385 results

NameH-indexPapersCitations
Sanjay Kumar120205282620
John A. Katzenellenbogen9569136132
Brajesh K. Singh8340124101
Gaurav Sharma82124431482
Sudhir Kumar82524216349
Pramod K. Srivastava7939027330
Mohan K. Raizada7547321452
Syed F. Ali7144618669
Ravi Shankar6667219326
Ramesh Chandra6662016293
Manoj Kumar6540816838
Manish Kumar61142521762
Anil Kumar Saxena5831010107
Sanjay Krishna5662413731
Naibedya Chattopadhyay562429795
Network Information
Related Institutions (5)
Merck & Co.
48K papers, 1.9M citations

93% related

GlaxoSmithKline
21.1K papers, 1.1M citations

92% related

Bristol-Myers Squibb
21K papers, 932.5K citations

92% related

Novartis
50.5K papers, 1.9M citations

91% related

Pfizer
37.4K papers, 1.6M citations

91% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20233
202255
2021306
2020232
2019246
2018289